KR102440820B1 - ApoA-1 융합 폴리펩티드 및 관련 조성물 및 방법 - Google Patents

ApoA-1 융합 폴리펩티드 및 관련 조성물 및 방법 Download PDF

Info

Publication number
KR102440820B1
KR102440820B1 KR1020187009391A KR20187009391A KR102440820B1 KR 102440820 B1 KR102440820 B1 KR 102440820B1 KR 1020187009391 A KR1020187009391 A KR 1020187009391A KR 20187009391 A KR20187009391 A KR 20187009391A KR 102440820 B1 KR102440820 B1 KR 102440820B1
Authority
KR
South Korea
Prior art keywords
delete delete
seq
amino acid
polypeptide
fusion polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187009391A
Other languages
English (en)
Korean (ko)
Other versions
KR20180040711A (ko
Inventor
마타 에스. 헤이든-레드베터
제프리 에이. 레드베터
빈스 몬테스
Original Assignee
테리피온, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테리피온, 인크. filed Critical 테리피온, 인크.
Publication of KR20180040711A publication Critical patent/KR20180040711A/ko
Application granted granted Critical
Publication of KR102440820B1 publication Critical patent/KR102440820B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01002—Arylesterase (3.1.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01047—1-Alkyl-2-acetylglycerophosphocholine esterase (3.1.1.47), i.e. platelet-activating factor acetylhydrolase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/08—Phosphoric triester hydrolases (3.1.8)
    • C12Y301/08001—Aryldialkylphosphatase (3.1.8.1), i.e. paraoxonase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
    • C12Y301/27005—Pancreatic ribonuclease (3.1.27.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
KR1020187009391A 2015-09-08 2016-09-06 ApoA-1 융합 폴리펩티드 및 관련 조성물 및 방법 Active KR102440820B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562215256P 2015-09-08 2015-09-08
US62/215,256 2015-09-08
PCT/US2016/050405 WO2017044424A1 (en) 2015-09-08 2016-09-06 Apoa-1 fusion polypeptides and related compositions and methods

Publications (2)

Publication Number Publication Date
KR20180040711A KR20180040711A (ko) 2018-04-20
KR102440820B1 true KR102440820B1 (ko) 2022-09-05

Family

ID=56985674

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187009391A Active KR102440820B1 (ko) 2015-09-08 2016-09-06 ApoA-1 융합 폴리펩티드 및 관련 조성물 및 방법

Country Status (10)

Country Link
US (4) US12331102B2 (enExample)
EP (1) EP3328881B1 (enExample)
JP (3) JP6953020B2 (enExample)
KR (1) KR102440820B1 (enExample)
CN (1) CN107969127B (enExample)
AU (1) AU2016321146C1 (enExample)
CA (1) CA2997263C (enExample)
DK (1) DK3328881T3 (enExample)
IL (1) IL257302B (enExample)
WO (1) WO2017044424A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
AU2019240609B2 (en) * 2018-10-29 2025-12-11 Consejo Nacional de Investigaciones Científcas Y Técnicas (Conicet) TGF- ß receptor II isoform, fusion peptide, methods of treatment and methods in vitro
JP7316711B2 (ja) * 2019-08-19 2023-07-28 ナンジン・ノベル・バイオテクノロジー・カンパニー・リミテッド 脂質代謝を調節する複製腫瘍溶解性アデノウイルス及びその応用
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
US12180521B2 (en) 2021-02-19 2024-12-31 Theripion, Inc. Paraoxonase fusion polypeptides and related compositions and methods
KR20250029793A (ko) * 2022-05-24 2025-03-05 바이오-트립 비.브이. 지질 나노입자를 위한 표적화 바디를 갖는 변형된 아포리포단백질
WO2024158816A1 (en) * 2023-01-23 2024-08-02 The Board Of Trustees Of The Leland Stanford Junior University Conjugates, compositions, and methods for brain delivery
WO2024251979A1 (en) * 2023-06-07 2024-12-12 Universidad Del País Vasco/Euskal Herriko Unibertsitatea Backpacked-antibody constructs and their uses
WO2024259220A1 (en) 2023-06-15 2024-12-19 Theripion, Inc. Pon3 and evolved pon1 fusion polypeptides
CN118077649B (zh) * 2024-02-29 2024-09-10 复旦大学附属中山医院 一种免疫检查点抑制剂构建动脉粥样硬化小鼠模型的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030008373A1 (en) 2001-04-17 2003-01-09 Myriad Genetics, Incorporated APOA1-interacting proteins and use thereof
US20040115183A1 (en) 2000-12-26 2004-06-17 Aharon Rabinkov Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-senstive diseases
US20110178029A1 (en) 2007-09-14 2011-07-21 Ambrx, Inc. Modified Human Apolipoprotein A-1 and Their Uses
WO2013127752A1 (en) 2012-02-29 2013-09-06 F. Hoffmann-La Roche Ag Method for reduction of 1->3 reading frame shifts
US20140363428A1 (en) 2011-09-30 2014-12-11 Chugai Seiyaku Kabushiki Kaisha THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK368882A (da) 1981-08-25 1983-02-26 Alan John Kingsman Expessions vektorer
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
EP0184576B1 (en) 1984-12-06 1990-06-27 Fina Research S.A. Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
EP0749319A1 (en) 1992-09-14 1996-12-27 Pfizer Inc. Immortalized cells and uses therefor
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5795572A (en) 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
US6258596B1 (en) * 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
CN1230997A (zh) 1996-07-17 1999-10-06 津莫吉尼蒂克斯公司 甲醇毕赤酵母的转化
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
WO2002038609A2 (en) 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
US7217785B2 (en) * 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
DK1436003T3 (da) 2001-05-24 2010-03-15 Zymogenetics Inc TACI-immunoglobulin-fusionsproteiner
US20030049694A1 (en) * 2001-09-10 2003-03-13 Chung-Hsiun Wu Production of fusion proteins and use for identifying binding molecules
US7691965B2 (en) * 2002-05-08 2010-04-06 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
CN1926237A (zh) * 2004-01-28 2007-03-07 森托尼克斯制药有限公司 用于治疗不育症的异二聚体促卵泡激素－Fc(FSH－Fc)融合蛋白
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
MX2007013924A (es) 2005-05-09 2008-01-28 Glycart Biotechnology Ag Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc.
EP1896579A2 (en) 2005-06-16 2008-03-12 Wisconsin Alumni Research Foundation Cytotoxic ribonuclease variants
KR20090057936A (ko) * 2006-02-08 2009-06-08 타게티드 몰레큘라 다이아그노스틱스, 엘엘씨 2가 ｅｒｂｂ 리간드 결합 분자 및 그의 제조 방법 및 사용방법
EP1867660A1 (en) 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
DK2222697T3 (da) * 2007-11-01 2013-03-11 Perseid Therapeutics Llc Immunsuppressive polypeptider og nukleinsyrer
BRPI0915093A2 (pt) * 2008-06-13 2015-10-27 Proyecto Biomedicina Cima Sl conjugados para a administração de compostos biologicamente ativos
US20100098693A1 (en) * 2008-10-07 2010-04-22 Pardridge William M Compositions and methods for blood-brain barrier delivery of organophosphatases
CN102070717B (zh) * 2009-11-19 2013-04-10 东莞太力生物工程有限公司 融合蛋白及其制备方法、编码该蛋白的dna序列、表达载体、宿主细胞、含有该蛋白的药物组合物
US9260529B2 (en) 2010-02-24 2016-02-16 The University Of Washington Through Its Center For Commercialization Molecules that bind CD180, compositions and methods of use
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
LT2647707T (lt) * 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Citotoksiškumą indukuojantis terapinis agentas
JP6063450B2 (ja) 2011-04-29 2017-01-18 ユニヴァーシティ オブ ワシントン 治療用ヌクレアーゼ組成物および方法
AR090281A1 (es) * 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
US20140120091A1 (en) 2012-10-31 2014-05-01 University Of Washington Through Its Center For Commercialization Fusion proteins for therapy of autoimmune and cardiovascular disease
EP2948162A1 (en) * 2013-01-25 2015-12-02 Lagerstedt, Jens Apolipoprotein a-i derived peptides for treatment of hyperglycaemia
BR112015027968A2 (pt) * 2013-05-14 2017-10-17 Bayer Cropscience Nv expressão seletiva melhorada de transgenes em plantas produtoras de fibras
HRP20192080T1 (hr) 2013-10-31 2020-02-07 Resolve Therapeutics, Llc Terapeutske fuzije nukleaza-albumine i postupci
US20160009776A1 (en) 2014-07-10 2016-01-14 Bayer Pharma Aktiengesellschaft Pdgfrbeta-fc fusion proteins and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115183A1 (en) 2000-12-26 2004-06-17 Aharon Rabinkov Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-senstive diseases
US20030008373A1 (en) 2001-04-17 2003-01-09 Myriad Genetics, Incorporated APOA1-interacting proteins and use thereof
US20110178029A1 (en) 2007-09-14 2011-07-21 Ambrx, Inc. Modified Human Apolipoprotein A-1 and Their Uses
US20140363428A1 (en) 2011-09-30 2014-12-11 Chugai Seiyaku Kabushiki Kaisha THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE
WO2013127752A1 (en) 2012-02-29 2013-09-06 F. Hoffmann-La Roche Ag Method for reduction of 1->3 reading frame shifts

Also Published As

Publication number Publication date
CA2997263A1 (en) 2017-03-16
IL257302B (en) 2022-05-01
NZ738963A (en) 2021-08-27
JP2022105200A (ja) 2022-07-12
EP3328881B1 (en) 2019-08-28
AU2016321146C1 (en) 2021-10-28
JP7233113B2 (ja) 2023-03-06
US20220089687A1 (en) 2022-03-24
CN107969127B (zh) 2022-09-06
JP6953020B2 (ja) 2021-10-27
AU2016321146B2 (en) 2020-10-29
JP2021036917A (ja) 2021-03-11
EP3328881A1 (en) 2018-06-06
AU2016321146A1 (en) 2018-02-01
IL257302A (en) 2018-03-29
CA2997263C (en) 2022-10-04
US20250206806A1 (en) 2025-06-26
US11472864B2 (en) 2022-10-18
JP2018531622A (ja) 2018-11-01
WO2017044424A1 (en) 2017-03-16
US20180201664A1 (en) 2018-07-19
CN107969127A (zh) 2018-04-27
US12331102B2 (en) 2025-06-17
US20230024372A1 (en) 2023-01-26
DK3328881T3 (da) 2019-10-07
KR20180040711A (ko) 2018-04-20

Similar Documents

Publication Publication Date Title
KR102440820B1 (ko) ApoA-1 융합 폴리펩티드 및 관련 조성물 및 방법
JP6348448B2 (ja) Ａｌｋ１受容体およびリガンドアンタゴニストならびにその使用
KR102696275B1 (ko) 염증을 치료 및 예방하기 위한 조성물 및 방법
CN107970445A (zh) Bmp-alk3拮抗剂和促进骨生长的用途
EP3060235B1 (en) Endoglin peptides to treat fibrotic diseases
KR20140123558A (ko) Alk1 길항제 및 신세포 암종 치료에서의 그의 용도
CN108623691A (zh) IgG样长效免疫融合蛋白及其应用
JP2023027301A (ja) キメラ凝固因子を使用して血友病性関節症を処置する方法
KR20220058586A (ko) 치료용 융합 단백질
KR102461210B1 (ko) Uti 융합 단백질
JP2018529729A (ja) 胆汁酸障害の処置
WO2018136163A2 (en) Tandem apoa-1 fusion polypeptides
NZ738963B2 (en) Apoa-1 fusion polypeptides and related compositions and methods
JP7094223B2 (ja) 病的な筋肉減少および筋力低下の処置のためのｎｏｐｅ
HK1228288A1 (en) Endoglin peptides to treat fibrotic diseases
HK1228288B (en) Endoglin peptides to treat fibrotic diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4